COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 14 of 26 for:    inflammation | Bipolar Disorder

12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02363738
Recruitment Status : Unknown
Verified February 2018 by University Health Network, Toronto.
Recruitment status was:  Active, not recruiting
First Posted : February 16, 2015
Last Update Posted : February 26, 2018
Clinical Investigation Centre for Innovative Technology Network
Stanford University
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
Studies show the presence of immuno-inflammatory disturbances in individuals with Bipolar Disorders (BD). Increased levels of circulating proteins known as cytokines that promote inflammation have been consistently reported in individuals with bipolar disorders. A particular cytokine referred to as Tumor Necrosis Factor (TNF)-alpha is among those cytokines that have been consistently identified across depressive, manic, and euthymic periods. Disturbances in inflammation however, are not seen in all individual with bipolar disorder. Those individuals with signs of inflammation also often present with higher prevalence of medical disorders that are also associated with inflammation. Those individuals with significant signs of inflammation may respond to anti-inflammatory treatments. In this study, individuals with bipolar depression who exhibit signs of high inflammation will be enrolled and treated with either an anti-inflammatory biologic known as infliximab or placebo (saline).

Condition or disease Intervention/treatment Phase
Bipolar Depression Drug: Infliximab Other: Saline Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multisite, Fixed Dose, Randomized, Double-Blind, Placebo-Controlled 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression
Study Start Date : September 2015
Estimated Primary Completion Date : April 2018
Estimated Study Completion Date : April 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Infliximab

Arm Intervention/treatment
Experimental: Infliximab
Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation
Drug: Infliximab
Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
Other Name: Remicade

Placebo Comparator: Saline (Placebo)
Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.
Other: Saline
Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.

Primary Outcome Measures :
  1. Change from baseline in the Montgomery-Asberg Depression Rating Scale score [ Time Frame: Up to 12 weeks ]

Secondary Outcome Measures :
  1. Change in cytokine levels in the blood [ Time Frame: Up to 12 weeks ]
  2. Change in cognitive function (including executive function, attention, memory) [ Time Frame: Up to 12 weeks ]
  3. Change in brain volume and neuroprogression evaluated via neuroimaging (MRI and MRS) [ Time Frame: Up to 12 weeks ]
  4. Change in quality of life as measured by 36-Item Short Form Health Survey [ Time Frame: Up to 12 weeks ]
  5. Change in functional ability as measured by Sheehan Disability Scale and Endicott Workplace productivity Scale [ Time Frame: Up to 12 weeks ]
  6. Suicide risk will be assessed as a safety measure using the Columbia Suicide Severity Rating Scale [ Time Frame: Up to 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Fifth edition of Diagnostic and Statistical Manual for Mental Disorders (DSM-5) criteria for major depressive episode as part of bipolar I/II disorder and are able to provide written informed consent
  • HAMD-17 score >= 20
  • Young Mania Rating Scale score < 12
  • Previous failed trial (i.e., inefficacy) of quetiapine and one other Canadian Network for Mood and Anxiety Treatments (CANMAT) BD guideline/FDA approved first line treatment for the depressive phase of BD during the index episode and/or during a prior episode
  • Currently prescribed conventional mood stabilizer or atypical antipsychotic agent
  • Received conventional treatment for bipolar depression for a minimum of 4 weeks prior to randomization
  • Females of childbearing potential must test negative for pregnancy and must be using adequate birth control measures throughout the study and must continue such precautions for 6 months after receiving the last study drug administration.

Participants will also need to meet one of the following inflammatory indicators:

  1. Central Obesity (ethnicity-specific waist circumference - see table below for specific values) OR BMI ≥30 kg/m2.


    • Raised triglycerides: ≥1.7 mmol/L (150 mg/dL) or specific treatment for this lipid abnormality OR
    • Reduced HDL-cholesterol: <1.03 mmol/L (40 mg/dL) in males; <1.29 mmol/L (50 mg/dL) in females or specific treatment for this lipid abnormality OR
    • Raised Blood Pressure: Raised blood pressure Systolic: ≥130 mm Hg or diastolic: ≥85 mm Hg or treatment of previously diagnosed hypertension.
  2. Diabetes: 8-hour fasting plasma glucose ≥ 7.0 mmol/L or Hb-A1C test ≥ 6.5% (as per the 2013 CDA diagnostic criteria) or previously diagnosed type 1 or 2 diabetes (current prescription medication for diabetes acceptable of diagnosis). Participants with child onset of diabetes will be excluded.
  3. Inflammatory bowel disorder (Ulcerative Colitis, Crohn's disease).
  4. Rheumatological disorders (rheumatoid arthiristis); Psoriasis.
  5. Smoking cigarettes (daily - minimum of ½ pack).
  6. High sensitivity C-reactive protein level of ≥5 mg/L via blood test at screening

Exclusion Criteria:

  • Another concurrent psychiatric disorder that requires primary clinical attention
  • History of schizophrenia
  • Active psychotic symptoms
  • Substance abuse and/or dependence within past 6 months
  • Electroconvulsive therapy in the past 6 months
  • Actively suicidal or evaluated as being a suicide risk [HAMD-17 suicide item >= 3 or Montogomery Asberg Depression Rating Scale (MADRS) suicide item >= 4, or according to clinical judgement using the C-SSRS]
  • Clinically significant unstable medical illness
  • Severe infections such as sepsis, abscess, tuberculosis and opportunistic infections
  • Viral hepatitis B
  • History of Hepatitis C ( documented or suspected)
  • Any autoimmune disorder
  • History of tuberculosis or a high risk of tuberculosis exposure
  • Human Immunodeficiency Virus confirmed by laboratory testing
  • Active fungal infection
  • History of recurrent viral or bacterial infections
  • Received within 3 months prior to screening or are expected to receive any live viral vaccine or live bacterial vaccinations during the trial or up to 3 months after the last administration of study agent
  • C. difficile infection within the past 4 months
  • History of lymphoproliferative disease
  • History of cancer, excluding basal cell or squamous cell carcinoma of the skin (fully excised with no recurrence)
  • Unstable cardiovascular, endocrinological, hematological, hepatic, renal or neurological disease determined by physical examination and laboratory testing
  • Concomitant diagnosis or any history of congestive heart failure
  • Concomitant treatment with non-steroidal and steroidal anti-inflammatory medications or other biologics
  • Current or past exposure to anti-TNF biologics
  • Previous immediate hypersensitivity response, including anaphylaxis to an immunoglobulin product (plasma-derived or recombinant, e.g. monoclonal antibody)
  • Known allergies, hypersensitivity or intolerance to infliximab or its excipients
  • Known allergy to murine proteins or other chimeric proteins
  • Currently on or have used any investigational drug within 30 days prior to screening, or within 5 half-lives of the investigational agent
  • Females who are pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02363738

Layout table for location information
United States, California
VA Palo Alto Health Care System
Palo Alto, California, United States, 94304
Canada, Ontario
Toronto Western Hospital
Toronto, Ontario, Canada, M5T2S8
Sponsors and Collaborators
University Health Network, Toronto
Clinical Investigation Centre for Innovative Technology Network
Stanford University
Layout table for investigator information
Principal Investigator: Roger S McIntyre, MD, FRCPC University of Toronto; University Health Network

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University Health Network, Toronto Identifier: NCT02363738    
Other Study ID Numbers: Infliximab-BD
First Posted: February 16, 2015    Key Record Dates
Last Update Posted: February 26, 2018
Last Verified: February 2018
Keywords provided by University Health Network, Toronto:
Bipolar Disorder
Bipolar Depression
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Bipolar Disorder
Mood Disorders
Mental Disorders
Bipolar and Related Disorders
Behavioral Symptoms
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents